Genelux GNLX
NASDAQ GNLX
$1.98 -0.09 (-4.35%)
At close: Oct 22, 2026 · 4:00 PM EDT

Genelux (GNLX) Return on Sales [ROS] (2022 - 2024)

Updated

Genelux (GNLX) recorded Return on Sales [ROS] of -415175.00% in FY2025, down 18975.00 percentage points from -396200.00% in FY2024.

Analysis

Genelux (GNLX) Return on Sales [ROS] (2022 - 2024) Analysis & Trends

Starting with FY2022, Genelux's Return on Sales [ROS] history includes 4 years.

  • Annual Return on Sales [ROS] has declined for three straight years, with a three-year change of -415147.78 percentage points (FY2022 to FY2025).
  • Per Business Quant data, GNLX's Return on Sales [ROS] was -396200.00% in FY2024 (-381985.29 pp), -14214.71% in FY2023 (-14187.48 pp) and -27.22% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn 24.35%
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn 37.86%
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn -3.52%
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn 32.97%
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn 20.57%
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn -133.21%
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn 28.37%
10 Genelux 87.86 Mn 26.14 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -396,200.00%
Sep 30, 2024 -361,862.50%
Jun 30, 2024 -341,437.50%
Mar 31, 2024 -101,437.50%
Dec 31, 2023 -14,214.71%
Sep 30, 2023 -8,511.76%
Jun 30, 2023 -76.59%
Mar 31, 2023 -3,801.18%
Dec 31, 2022 -4,550.00%
Sep 30, 2022 57.67%
API Access

Genelux Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=GNLX&period=max&api_key=YOUR_API_KEY